HIMS Stock Extends 3-Day Rally: Hims & Hers Targets GLP-1 Gold Rush In Canada After Novo Nordisk Patent Expiry
The launch follows Novo Nordisk’s failure to pay a C$250 patent maintenance fee in Canada. Hims launched generic…
Browsing Tag